{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:33Z","timestamp":1791563133412,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,2]]},"abstract":"\n Aims<\/jats:title>\n \n Among patients with type 2 diabetes and albuminuria, cardiorenal morbidity and mortality are high despite multifactorial treatment. Short\u2010term reduction in albuminuria is considered suggestive of long\u2010term renoprotective effects. We evaluated the renal effects of the glucagon\u2010like peptide\u20101 (\n GLP<\/jats:styled-content>\n \u20101) receptor agonist liraglutide on top of multifactorial care, including renin\u2010angiotensin\u2010system (\n RAS<\/jats:styled-content>\n )\u2010inhibition.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n Randomized, double\u2010blind, placebo\u2010controlled, cross\u2010over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin\u2010to\u2010creatinine ratio >30 mg\/g) and estimated glomerular filtration rate (\n eGFR<\/jats:styled-content>\n ) \u226530\n mL<\/jats:styled-content>\n \/min\/1.73 m\n 2<\/jats:sup>\n . Patients received liraglutide (1.8 mg\/d) and matched placebo for 12 weeks in a random order. The primary endpoint was change in 24\u2010h urinary albumin excretion rate (\n UAER<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 32 patients were randomized and 27 completed the study. After placebo treatment, geometric mean (\n IQR<\/jats:styled-content>\n )\n UAER<\/jats:styled-content>\n was 199 (81\u2010531) mg\/24\u2010h, mean (\n SD<\/jats:styled-content>\n ) measured\n GFR<\/jats:styled-content>\n (\n mGFR<\/jats:styled-content>\n ) 75 (36)\n mL<\/jats:styled-content>\n \/min\/1.73 m\n 2<\/jats:sup>\n , 24\u2010h blood pressure 145\/80 (15\/8)\n mm Hg<\/jats:styled-content>\n and\n HbA1c<\/jats:styled-content>\n 61 (11) mmol\/mol. Liraglutide reduced\n HbA1c<\/jats:styled-content>\n by 8 (95%\n CI<\/jats:styled-content>\n : 5; 11) mmol\/mol (\n P<\/jats:italic>\n < .001) and weight by 1.8 (95%\n CI<\/jats:styled-content>\n : 0.2; 3.4) kg (\n P<\/jats:italic>\n = .032) compared to placebo. Furthermore, liraglutide reduced\n UAER<\/jats:styled-content>\n by 32 (95%\n CI<\/jats:styled-content>\n : 7; 50)% (\n P<\/jats:italic>\n = .017) compared with placebo. The change in\n mGFR<\/jats:styled-content>\n was \u22125 (95%\n CI<\/jats:styled-content>\n : \u221211; 2)\n mL<\/jats:styled-content>\n \/min\/1.73 m\n 2<\/jats:sup>\n (\n P<\/jats:italic>\n = .15), and change in 24\u2010h systolic blood pressure was \u22125 (95%\n CI<\/jats:styled-content>\n : \u221210; 0)\n mm Hg<\/jats:styled-content>\n (\n P<\/jats:italic>\n = .07). In multivariate regression models, change in\n UAER<\/jats:styled-content>\n was associated with change in 24\u2010h systolic blood pressure (\n P<\/jats:italic>\n = .025) but not with change in\n HbA1c<\/jats:styled-content>\n , weight or\n mGFR<\/jats:styled-content>\n (\n P<\/jats:italic>\n \u2265 .14), overall model\n \n R\n 2<\/jats:sup>\n <\/jats:italic>\n = .39.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Our placebo\u2010controlled randomized trial suggests that liraglutide has renoprotective effects on top of multifactorial treatment, including\n RAS<\/jats:styled-content>\n \u2010inhibition, in patients with type 2 diabetes and albuminuria.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12808","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T21:52:39Z","timestamp":1476741159000},"page":"239-247","source":"Crossref","is-referenced-by-count":93,"title":["The effect of liraglutide on renal function: A randomized clinical trial"],"prefix":"10.1111","volume":"19","author":[{"given":"Bernt J.","family":"von Scholten","sequence":"first","affiliation":[{"name":"Department of Diabetes Complications Research, Steno Diabetes Center Gentofte Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Department of Diabetes Complications Research, Steno Diabetes Center Gentofte Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Rosenlund","sequence":"additional","affiliation":[{"name":"Department of Diabetes Complications Research, Steno Diabetes Center Gentofte Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hovind","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology & Nuclear Medicine & PET, Rigshospitalet, Glostrup Hospital Glostrup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Herlev University Hospital Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine W.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Diabetes Complications Research, Steno Diabetes Center Gentofte Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Department of Diabetes Complications Research, Steno Diabetes Center Gentofte Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen Copenhagen Denmark"},{"name":"Health, Aarhus University Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.427"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12594"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2883"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00653.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.4.421"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139860.33974.28"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050140"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070688"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12651"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00429.2014"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365517209084290"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7441.702"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.490"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080830"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16014"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00261-2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12654"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00527.2014"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.009"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03062"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1958"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.04.004"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1371"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.08.007"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.79"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.111"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:20:30Z","timestamp":1761862830000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/dom.12808"],"URL":"https:\/\/doi.org\/10.1111\/dom.12808","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}